VivoSeq
Other

MASLD

0

Pipeline Programs↗

8

Active Trials↗

4

Companies Involved↗

MASLD is an early-stage landscape with 0 programs across 4 companies. The most active players are Zhejiang Doer Biologics Co., Ltd., Eli Lilly, Corcept Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zhejiang Doer Biologics Co., Ltd.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2C

Corcept Therapeutics

0 programs

PreclinicalA

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Recruiting4 · 40%
Not yet recruiting3 · 30%
Completed2 · 20%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation
Recruiting·LLeeuwenhoek Laboratories Co. Ltd.·Phase 1·NCT07488975·40 enrolled
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Recruiting·CCorcept Therapeutics·Phase 1·NCT06947304·8 enrolled
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity: Randomized, Open-label, Parallel Group, Controlled Superiority Trial _ CHRONOSTEATOSIS
Recruiting·NNantes University Hospital·Preclinical·NCT07378072·72 enrolled
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers - Study Protocol Version 2.0
Recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Preclinical·NCT07652151·450 enrolled
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of DR10624 Injection in Subjects at High Risk of Liver Fibrosis With Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction and Alcohol Associated Steatotic Liver Disease
Active, not recruiting·ZZhejiang Doer Biologics Co., Ltd.·Phase 2·NCT07024212·110 enrolled
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Not yet recruiting·—·Phase 2·NCT07143968·120 enrolled
SMART Diets for MASLD
Not yet recruiting·CCorewell Health West·Phase 2·NCT07459504·102 enrolled
Assessment of the Accuracy of FIB-4 Cut-Offs for the Prediction of Liver Fibrosis in Obese Patients Attending Endocrinology Clinics in Italy
Not yet recruiting·AAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis·N/A·NCT07663188·400 enrolled
Benefits of Trimetazidine in MASLD Patients
Completed·OOctober 6 University·Phase 2·NCT06140953·60 enrolled
NIMIT-AI: Neural Inference for Metabolic-liver Integrated Trajectories: Leveraging Deep Learning to Enhance Reliability in MASLD Triage
Completed·SSiriraj Hospital·N/A·NCT07675525·1,351 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)